Ignite Creation Date:
2024-10-25 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06647706
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-16
Brief Title:
Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the MPNs patients for the presence of PH by using a non invasive method Transthoracic echocardiography TTE and correlate the clinical and laboratory data of these patients with development of PH aiming to identify risk factors for PH and parameters that can predict PH in MPNs patients and thusidentifying MPNs patients who require close monitoring screening for PH hoping that early detection and management of PH in MPNs patients can improve morbidity prognosis and survival in those patients
Detailed Description:
Pulmonary hypertension PH is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive increase in the pulmonary vascular load PH is a serious complex disorder that associated with high morbidity and mortality rates
PH is a complication of various hematologic diseases including myeloproliferative neoplasms MPNs which are included in group 5 ph
Myeloproliferative neoplasms MPNs are a group of diseases characterized by uncontrolled proliferation of at least one myeloid series due to an abnormal hematopoietic cell clone There are different types of MPNs including polycythemia vera PV essential thrombocythemia ET chronic myeloid leukemia CML and primary myelofibrosis PMF
PH is defined as an elevation in the mean pulmonary artery pressure mPAP that is greater than or equal to 25 mmHg which was measured at rest via right heart catheterization RHC
Systolic pulmonary artery pressure sPAP can be accurately estimated using Doppler transthoracic echocardiography TTE recent advances in noninvasive imaging led Doppler TTE to become the most widespread and well-recognized technique for non-invasive sPAP evaluation and the screening modality of choice for evaluating PH
Active monitoring of PH in patients with MPN may be warranted Identification of risk factors predicting PH in MPN patients promises early detection and possibly improved PH management and therapy
PH is a complication of various hematologic diseases including myeloproliferative neoplasms MPNs which are included in group 5 ph
Myeloproliferative neoplasms MPNs are a group of diseases characterized by uncontrolled proliferation of at least one myeloid series due to an abnormal hematopoietic cell clone There are different types of MPNs including polycythemia vera PV essential thrombocythemia ET chronic myeloid leukemia CML and primary myelofibrosis PMF
PH is defined as an elevation in the mean pulmonary artery pressure mPAP that is greater than or equal to 25 mmHg which was measured at rest via right heart catheterization RHC
Systolic pulmonary artery pressure sPAP can be accurately estimated using Doppler transthoracic echocardiography TTE recent advances in noninvasive imaging led Doppler TTE to become the most widespread and well-recognized technique for non-invasive sPAP evaluation and the screening modality of choice for evaluating PH
Active monitoring of PH in patients with MPN may be warranted Identification of risk factors predicting PH in MPN patients promises early detection and possibly improved PH management and therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None